For personal use only
Improving Lives
Phase I/II Trial Results Webinar
July 2022
Dr Alexandra Andrews | Brian Leedman | Gerald Quigley |
PhD Neuroscience, BBMed Sci (Hons1st) | BEc, MBA (UWA) | B(Pharm) |
Chief Executive Officer | Chairman | Non-Executive Director |
For personal use only
Disclaimer
IMPORTANT INFORMATION
Purpose of presentation: This presentation (including this document, any related video or oral presentation, any question and answer session and any written or oral material discussed or distributed in relation to this presentation) has been prepared by Neurotech International Limited (ACN 610 205 402) (Neurotech or Company). It has been prepared for the sole purpose of providing general information on Neurotech and its business.
Not an offer or solicitation: This presentation is not investment advice nor an offer to subscribe for securities or otherwise invest in Neurotech, and it should not be relied upon to make any investment decision. Further, it does not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of securities pursuant to this presentation in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful under applicable law, including the Securities Act of 1933 (USA), as amended (US Securities Act). Securities have not been registered under the US Securities Act or any US state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the US Securities Act and applicable state securities laws.
Not a prospectus: This presentation is not a prospectus, product disclosure statement or other investment disclosure document, and the level of disclosure in this presentation is less than such disclosure documents. It has not been lodged with any regulatory or supervisory body. This presentation does not purport to contain all of the information that a prospective investor may require to make an evaluation of Neurotech or its business activities and nothing in this presentation is, or is intended to be, a recommendation to invest in Neurotech. Neurotech does not purport to give financial or investment advice. Account has not been taken of the objectives, financial situation or needs of any recipient of this presentation.
Forward-lookingstatements: This presentation contains forward-looking statements which may be predictive in nature and incorporate an element of uncertainty or risk, such as 'intends', 'may', 'could', 'believes', 'estimates', 'targets' or 'expects'. These statements are based on an evaluation of current economic and operating conditions, as well as assumptions regarding future events.
These events are, as at the date of this presentation, expected to take place, but there cannot be any guarantee that such will occur as anticipated, or at all, given that many of the events are outside Neurotech's control. The stated events may differ materially from results ultimately achieved. Accordingly, neither Neurotech nor any of its directors, employees, contractors or advisors make any warranty or assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this presentation will actually occur. Further, other than as required by law, Neurotech may not update
or revise any forward-looking statement if events subsequently occur or information subsequently becomes available that affects the original forward-looking statement.
Disclaimer: Neither Neurotech nor its officers, employees, contractors or advisers make any warranty (express or implied) as to the accuracy, reliability, relevance or completeness of the material contained in this presentation. Nothing contained in this presentation is, or may be relied upon as a promise, representation or warranty, whether as to the past or the future. Neurotech excludes all warranties that can be excluded by law. Except for statutory liability which cannot be excluded, Neurotech, its officers, employees, contractors and advisers expressly disclaim any responsibility for the accuracy or completeness of the material contained in this presentation and exclude all liability whatsoever (including in negligence) for any loss or damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom.
Professional advice: Recipients of this presentation should consider seeking appropriate professional financial, taxation and legal advice in reviewing the presentation and all other information with respect to Neurotech and evaluating its business, financial performance and operations.
Proprietary information and copyright: This presentation and the information it contains is proprietary to Neurotech. Neurotech holds the copyright in this presentation. Except as permitted under the Copyright Act 1968 (Australia), this paper or any part thereof may not be reproduced without its written permission.
2
For personal use only
Webinar Agenda - 8 July 2022
15 minute presentation
Dr Alexandra Andrews
CEO
Brian Leedman
Chairman
Gerald Quigley
Non-Executive Director
20 minute live Q & A
Brian Leedman
Chairman
3
use only
Neurotech is a biopharmaceutical company focused on the development & commercialisation of neurological solutions that improve quality of life.
For personal
Successful Phase I/II Trial 93% of patients showed improvement
PTC Patents lodged
World's first whole plant extract cannabis clinical study
Potential for NTI164 to treat neurological disorders
Exclusive worldwide licence
Neurotech's Mente device & therapy
4
For personal use only
Capital Structure
$0.075 | ~$52M | ~$2.33M |
Share price | Market | Cash at bank* |
(as at 1st July 2022) | capitalisation |
697M 143M^
Share on issue | Options/rights |
1. | *as at COB 31 March 2022 | 5 |
2. | ^Options are comprised at various strike prices between $0.005 to $0.09 as at 31 December 2021 | |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Neurotech International Ltd. published this content on 08 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 July 2022 03:23:00 UTC.